BioVie (BIVI) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for November 7, 2024, in a virtual format; record date is September 30, 2024.

• Stockholders will vote on director elections, auditor ratification, executive compensation, and an equity plan amendment.

• Board recommends voting in favor of all proposals.

• Proxy materials and annual report are available online; voting can be done by internet, phone, or mail.

Voting matters and shareholder proposals

• Six directors are up for election to serve until the next annual meeting.

• Proposal to ratify EisnerAmper LLP as independent auditor for fiscal 2025.

• Advisory vote on executive compensation (say-on-pay) is included.

• Proposal to amend and restate the 2019 Omnibus Equity Incentive Plan, increasing authorized shares by 1,250,000.

• Other business may be transacted as appropriate.

Board of directors and corporate governance

• Board consists of six directors, all current nominees, with diverse backgrounds in healthcare, finance, and communications.

• All directors attended at least 75% of board and committee meetings in fiscal 2024.

• Board has audit, compensation, and nominating/governance committees, all composed of independent directors.

• Code of ethics adopted and available on the company website.

• Board diversity matrix provided in compliance with Nasdaq rules.